Treatment of Moderate to Severe Refractory Crohn's Disease
NCT06721962
This study is recruiting at 13 US sites in 11 states, according to its ClinicalTrials.gov record last updated .
Summary
This research study is testing an investigational research product called TRX103 as a possible treatment for individuals suffering from Crohn's Disease (CD). The primary purpose of this study is to learn how safe and effective different doses of TRX103 are when administered to individuals with CD.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Crohns Disease
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Tr1X, Inc.
- Last updated on ClinicalTrials.gov
- December 10, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Mayo Clinic Arizona · Scottsdale, AZ
California · 2
- University of California, Davis · Sacramento, CA
- University of California, San Francisco · San Francisco, CA
Florida · 1
- University of Florida · Gainesville, FL
Illinois · 2
- Northwestern · Chicago, IL
- University of Chicago · Chicago, IL
Iowa · 1
- University of Iowa · Iowa City, IA
Kentucky · 1
- University of Louisville · Louisville, KY
Michigan · 1
- University of Michigan · Ann Arbor, MI
Minnesota · 1
- Mayo Clinic Rochester · Rochester, MN
Missouri · 1
- Washington University in St. Louis · St Louis, MO
New York · 1
- Mount Sinai Health Systems · New York, NY
Ohio · 1
- Cleveland Clinic · Cleveland, OH
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.